Evidence map›Paper›PMID 35861541›Full record

ArticleAntimicrobial agents and chemotherapy2022

Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.

Deiziane V S Costa, Natalie V S Pham, Rachel A Hays, David T Bolick, Sophia M Goldbeck, Melinda D Poulter, Sook C Hoang, Jae H Shin, Martin Wu, Cirle A Warren

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Isolating C. difficile from Animal Samples.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  5. Biomedicines · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Reduced Vancomycin Susceptibility inOpen forum infectious diseases · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Deiziane V S CostaUniversity of Virginiagrid.27755.32, Division of Infectious Diseases and International Health, Charlottesville, Virginia, USA.
Natalie V S PhamUniversity of Virginiagrid.27755.32, School of Medicine, Charlottesville, Virginia, USA.
Rachel A HaysUniversity of Virginiagrid.27755.32, Division of Gastroenterology and Hepatology, Charlottesville, Virginia, USA.
David T BolickUniversity of Virginiagrid.27755.32, Division of Infectious Diseases and International Health, Charlottesville, Virginia, USA.
Sophia M GoldbeckUniversity of Virginiagrid.27755.32, School of Medicine, Charlottesville, Virginia, USA.
Melinda D PoulterUniversity of Virginiagrid.27755.32, Department of Pathology, Charlottesville, Virginia, USA.
Sook C HoangUniversity of Virginiagrid.27755.32, Department of Surgery, Charlottesville, Virginia, USA.
Jae H ShinUniversity of Virginiagrid.27755.32, Division of Infectious Diseases and International Health, Charlottesville, Virginia, USA.
Martin WuUniversity of Virginiagrid.27755.32, Department of Biology, Charlottesville, Virginia, USA.
Cirle A WarrenUniversity of Virginiagrid.27755.32, Division of Infectious Diseases and International Health, Charlottesville, Virginia, USA.ORCID 0000-0002-4417-0445
University of Virginia · USUniversidade Federal do Ceará · BR

Funding

Alanyl-glutamine supplementation of standard treatment for C. difficile infectionR01AI145322 · NIAID · UNIVERSITY OF VIRGINIA · PI WARREN, CIRLE ALCANTARA · 2020 to 2024
$4.0M
NIAID NIH HHS R01 AI145322
6 · The paper itself

Abstract

Clostridioides difficile infection (CDI) is the fifth leading cause of death from nonmalignant gastrointestinal disease in the United States. The contribution of resistance to C. difficile-active antibiotics to the outcomes of CDI is unclear. We evaluated the antimicrobial susceptibility of C. difficile isolates in a U.S. hospital and determined associations of clinical variables and binary toxin positivity with antibiotic resistance. C. difficile spores were cultured from fecal specimens of adult patients with CDI for genotyping and antimicrobial susceptibility assay (for clindamycin [CLI], fidaxomicin [FDX], metronidazole [MTZ], moxifloxacin [MXF], tigecycline [TGC], and vancomycin [VAN]). Electronic medical records were reviewed for clinical data extraction. Ninety-seven of 130 (75%) fecal samples grew toxigenic C. difficile in culture. Most of the isolates were

Indexed as

Bacterial ToxinsClostridioides difficileClostridium InfectionsAdultAnti-Bacterial AgentsClostridioidesFidaxomicinHumansMetronidazoleMicrobial Sensitivity TestsMoxifloxacinSeverity of Illness IndexTigecyclineVancomycinAnti-Bacterial AgentsBacterial ToxinsFidaxomicinMetronidazoleMoxifloxacinTigecyclineVancomycinantibiotic resistancebinary toxinClostridioides difficilefidaxomicinmetronidazoletigecyclinevancomycin

Identifiers

PMID35861541
PMCPMC9380565
OpenAlexW4286491053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.